Aardvark Therapeutics (AARD) OKs option repricing, elects directors
Rhea-AI Filing Summary
Aardvark Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders held on August 14, 2026. Of 21,884,158 common shares outstanding as of the June 18, 2026 record date, 11,992,479 shares were represented, forming a 54.79% quorum. Stockholders elected Class I directors Victor Tong, Jr. and Jeffrey Chi, Ph.D. to serve until the 2029 annual meeting or until successors are elected and qualified. Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026. In addition, stockholders approved the repricing of certain outstanding stock options under the 2017 Plan, the 2025 Plan and the 2025 Inducement Plan held by eligible participants, based on the stated voting results.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding: 21,884,158 shares
Shares represented: 11,992,479 shares
Quorum percentage: 54.79%
+4 more
7 metrics
Shares outstanding
21,884,158 shares
Common stock outstanding as of June 18, 2026 record date
Shares represented
11,992,479 shares
Shares present virtually or by proxy at 2026 annual meeting
Quorum percentage
54.79%
Percentage of outstanding shares entitled to vote represented at the meeting
Votes for Victor Tong, Jr.
6,264,929
Votes for election as Class I director
Votes for Jeffrey Chi, Ph.D.
6,426,038
Votes for election as Class I director
Votes for auditor ratification
11,877,567
Votes for ratifying BDO USA, P.C. for year ending December 31, 2026
Votes for option repricing
4,649,269
Votes for repricing certain outstanding stock options under equity incentive plans
Key Terms
broker non-votes, independent registered public accounting firm, Equity Incentive Plan, Inducement Equity Incentive Plan
4 terms
broker non-votes financial
"Votes For | | Votes Against | | Abstentions | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"as the independent registered public accounting firm and independent auditor"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Equity Incentive Plan financial
"Aardvark Therapeutics, Inc. 2017 Equity Incentive Plan, as amended"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Inducement Equity Incentive Plan financial
"Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan"
An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.
FAQ
Which directors were elected at Aardvark Therapeutics (AARD) 2026 annual meeting and for how long?
Stockholders elected Victor Tong, Jr. and Jeffrey Chi, Ph.D. as Class I directors. They are each expected to serve until Aardvark Therapeutics’ 2029 annual meeting of stockholders, or until a respective successor is duly elected and qualified, based on the disclosed voting results.
How did Aardvark Therapeutics (AARD) stockholders vote on the auditor ratification for 2026?
Stockholders ratified BDO USA, P.C. as Aardvark Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026, with 11,877,567 votes for, 24,018 votes against, and 90,894 abstentions reported in the voting results.
What was the outcome of the stock option repricing proposal at Aardvark Therapeutics (AARD)?
Stockholders approved the repricing of certain outstanding stock options under the 2017, 2025 and 2025 Inducement equity incentive plans. The proposal received 4,649,269 votes for, 3,439,983 votes against, 73,809 abstentions, and 3,829,418 broker non-votes.
What equity plans were involved in Aardvark Therapeutics (AARD) option repricing approval?
The approved option repricing covered certain outstanding stock options under three plans: the 2017 Equity Incentive Plan, the 2025 Equity Incentive Plan, and the 2025 Inducement Equity Incentive Plan, applicable to options held by eligible participants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
